Dyne Therapeutics (DYN) Profit After Tax (2019 - 2026)

Dyne Therapeutics (DYN) has reported Profit After Tax for 8 consecutive years, with -$178.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Profit After Tax fell 61.26% year-over-year to -$178.8 million; the TTM figure through Jun 2026 stood at -$519.6 million (down 25.85% YoY), while the FY2025 annual figure was -$446.2 million, down 40.58% from the prior year.
• Profit After Tax declined to -$178.8 million in Q2 2026 per DYN's latest filing, from -$120.9 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$35.6 million in Q1 2022 and bottomed at -$178.8 million in Q2 2026.
• Historically, Profit After Tax has averaged -$81.5 million across 5 years, with a median of -$66.1 million in 2023.
• Annual changes were most pronounced in 2022 — Profit After Tax grew 26.15% — and 2025, when it slumped 75.72%.
• Dyne Therapeutics' Profit After Tax stood at -$38.4 million in 2022, then plunged by 73.47% to -$66.6 million in 2023, then slumped by 34.37% to -$89.5 million in 2024, then fell by 25.03% to -$112.0 million in 2025, then slumped by 59.68% to -$178.8 million in 2026.
• Business Quant data shows DYN's Profit After Tax at -$178.8 million in Q2 2026, -$120.9 million in Q1 2026, and -$112.0 million in Q4 2025.